Top 4 Stocks In The Biotechnology Industry With The Highest Revenue Estimates (AMGN, GILD, GENZ, BIIB)

Below are the top biotechnology stocks on the NYSE and the NASDAQ in terms of revenue estimates.

Amgen Inc (NASDAQ: AMGN) is expected to generate $15.10 billion of revenue in the current year. Analysts at Argus upgraded AMGN from “hold” to “buy.”

Gilead Sciences Inc (NASDAQ: GILD) is likely to generate $8.06 billion of revenue in the current year. GILD’s shares dipped 23.78% over the past 52 weeks, while the S&P 500 index gained 13.78% in the same period.

Genzyme Corporation (NASDAQ: GENZ) may generate $4.99 billion of revenue in this year. GENZ’s PEG ratio is 1.06.

The revenue estimates for Biogen Idec Inc (NASDAQ: BIIB) for the current year is $4.52 billion. BIIB’s PEG ratio is 1.12.

Trading Ideas.

You Can't Afford Miss Out On These Money Making Trading Ideas